VivoSeq
Other

Fetal Growth Restriction

15

Pipeline Programs↗

4

Active Trials↗

12

Companies Involved↗

Fetal Growth Restriction is an emerging landscape with 15 programs across 12 companies. The most active players are Hyundai Pharmaceutical Co., LTD., Azurity Pharmaceuticals, Neurim Pharmaceuticals Ltd.. 1 therapy is approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

43/100

Pipeline Velocity

6/100

Mech. Concentration

11/100

Completion Rate

57/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 1A

Azurity Pharmaceuticals

1 program

Phase 1N

Neurim Pharmaceuticals Ltd.

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

14

clinical trials

Completed4 · 29%
Unknown status3 · 21%
Terminated2 · 14%
Recruiting2 · 14%
Enrolling by invitation1 · 7%
Withdrawn1 · 7%
Other1 · 7%

Clinical Trials

Trial Activity

14 trials

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN)
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT05674487·774 enrolled
Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction
Recruiting·MMonash University·Phase 3·NCT05651347·336 enrolled
Patterns of Aortic Isthmus Doppler in Early Fetal Growth Restriction, Cross Sectional Comparative Study
Not yet recruiting·AAssiut University·N/A·NCT07676708·100 enrolled
LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)
Enrolling by invitation·—·Phase 3·NCT04762992·12 enrolled
A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction
Completed·—·Phase 3·NCT02590536·90 enrolled
Placental Lesions in Fetal Growth Restrictions
Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT04839185·3 enrolled
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction
Completed·—·Phase 1·NCT06565728·99 enrolled
Cook´s Balloon Versus Dinoprostone for Labor Induction of Term Pregnancies With Fetal Growth Restriction
Completed·HHospital Universitario 12 de Octubre·Phase 3·NCT05774236·172 enrolled
The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)
Terminated·—·Phase 2/3·NCT02277132·216 enrolled
LMWH to Prevent Preeclampsia and Fetal Growth Restriction
Terminated·UUniversity of Florence·N/A·NCT00260520
Transplacental Aspirin Therapy for Early Onset Fetal Growth Restriction
Withdrawn·JJohns Hopkins University·Phase 3·NCT04557475
Mode of Induction in Fetal Growth Restriction and Its Affects on Fetal and Maternal Outcomes
Unknown status·TTel-Aviv Sourasky Medical Center·Phase 1·NCT03625518·280 enrolled
OPtimal TIming of COrticosteroids in Early-onset Fetal Growth REstriction: the OPTICORE Study
Unknown status·UUMC Utrecht·N/A·NCT05606497·1,800 enrolled
Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment
Unknown status·—·Phase 3·NCT03230162·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)